Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 4/2016

01-08-2016 | SI: Challenges and Controversies in Translational Stroke Research

Various Cell Populations Within the Mononuclear Fraction of Bone Marrow Contribute to the Beneficial Effects of Autologous Bone Marrow Cell Therapy in a Rodent Stroke Model

Authors: Bing Yang, Kaushik Parsha, Krystal Schaar, XiaoPei Xi, Jaroslaw Aronowski, Sean I. Savitz

Published in: Translational Stroke Research | Issue 4/2016

Login to get access

Abstract

Cell-based therapies including bone-marrow derived mononuclear cells (MNCs) are now widely being studied because of their pleotropic effects and promising results to improve recovery after stroke in animal models. Unlike other types of cell therapies, MNCs is a mixture of lymphoid, myeloid, erythroid, and stem cell populations. Which cell population(s) accounts for the beneficial effects of MNCs in stroke recovery is unclear. In this paper, we employed a mouse stroke model with middle cerebral artery occlusion (MCAo), and used positively and negatively sorted autologous MNCs by MACs to determine which fractions of the MNCs contribute to their beneficial effects. We evaluated the benefits of neurofunctional recovery produced by individual cell lineages within MNCs in a long-term observation study up to 28 days after stroke. Mortality and modulation of inflammation were also compared among different sub-populations. We further studied the impact of neurotoxicity posed by activated microglia in the presence of different cell lineages within MNCs. We concluded that myeloid cell lineage and stem cell/progenitors appeared to be important components within MNCs that contribute to improved outcomes after stroke.
Literature
1.
Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab. 2012;32(7):1310–6.CrossRef
2.
Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis JD. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res. 2004;1007(1-2):1–9.CrossRefPubMed
3.
Kamiya N, Ueda M, Igarashi H, Nishiyama Y, Suda S, Inaba T, et al. Intra-arterial transplantation of bone marrow mononuclear cells immediately after reperfusion decreases brain injury after focal ischemia in rats. Life Sci. 2008;83(11-12):433–7.CrossRefPubMed
4.
Giraldi-Guimardes A, Rezende-Lima M, Bruno FP, Mendez-Otero R. Treatment with bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats. Brain Res. 2009;1266:108–20.CrossRefPubMed
5.
Brenneman M, Sharma S, Harting M, Strong R, Cox Jr CS, Aronowski J, et al. Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab. 2010;30(1):140–9.CrossRef
6.
Mendonca ML, Freitas GR, Silva SA, Manfrim A, Falcao CH, Gonzales C, et al. Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke. Arq Bras Cardiol. 2006;86(1):52–5.CrossRefPubMed
7.
Battistella V, de Freitas GR, da Fonseca LM, Mercante D, Gutfilen B, Goldenberg RC, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011;6(1):45–52.CrossRefPubMed
8.
Rosado-de-Castro PH, Schmidt Fda R, Battistella V, Lopes de Souza SA, Gutfilen B, Goldenberg RC, et al. Biodistribution of bone marrow mononuclear cells after intra-arterial or intravenous transplantation in subacute stroke patients. Regen Med. 2013;8(2):145–55.CrossRefPubMed
9.
Prasad K, Mohanty S, Bhatia R, Srivastava MV, Garg A, Srivastava A, et al. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res. 2012;136(2):221–8.PubMedPubMedCentral
10.
Prasad K, Sharma A, Garg A, Mohanty S, Bhatnagar S, Johri S, et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke J Cereb Circ. 2014;45(12):3618–24.CrossRef
11.
Savitz SI, Misra V, Kasam M, Juneja H, Cox Jr CS, Alderman S, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011;70(1):59–69.CrossRefPubMed
12.
Yang B, Strong R, Sharma S, Brenneman M, Mallikarjunarao K, Xi X, et al. Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res. 2011;89(6):833–9.CrossRefPubMedPubMedCentral
13.
Floden AM, Combs CK. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci. 2006;26(17):4644–8.CrossRefPubMed
14.
Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N, et al. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol. 2007;61(4):352–62.CrossRefPubMed
15.
Yang B, Xi X, Aronowski J, Savitz SI. Ischemic stroke may activate bone marrow mononuclear cells to enhance recovery after stroke. Stem Cells Dev. 2012;21(18):3332–40.CrossRefPubMedPubMedCentral
16.
Sharma S, Yang B, Strong R, Xi X, Brenneman M, Grotta JC, et al. Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. J Neurosci Res. 2010;88(13):2869–76.PubMedPubMedCentral
17.
Bedi SS, Walker PA, Shah SK, Jimenez F, Thomas CP, Smith P, et al. Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury. J Trauma Acute Care Surg. 2013;75(3):410–6.CrossRefPubMedPubMedCentral
18.
Leal MM, Costa-Ferro ZS, Souza BS, Azevedo CM, Carvalho TM, Kaneto CM, et al. Early transplantation of bone marrow mononuclear cells promotes neuroprotection and modulation of inflammation after status epilepticus in mice by paracrine mechanisms. Neurochem Res. 2014;39(2):259–68.CrossRefPubMed
19.
Guo X, Bu X, Li Z, Yan Z, Jiang J, Zhou Z. Comparison of autologous bone marrow mononuclear cells transplantation and mobilization by granulocyte colony-stimulating factor in experimental spinal injury. Int J Neurosci. 2012;122(12):723–33.CrossRefPubMed
20.
Kanamaru T, Kamimura N, Yokota T, Nishimaki K, Iuchi K, Lee H, et al. Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer’s disease. Brain Res. 2015.
21.
Nakano-Doi A, Nakagomi T, Fujikawa M, Nakagomi N, Kubo S, Lu S, et al. Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction. Stem Cells (Dayton, Ohio). 2010;28(7):1292–302.
22.
Prabhakar S, Muthaian R, Chabbra R, Anand A. Analysis of homing potential of marrow-derived mononuclear cells in an experimentally-induced brain stroke mouse model. Brain Inj. 2010;24(12):1485–90.CrossRefPubMed
23.
24.
25.
Yang B, Migliati E, Parsha K, Schaar K, Xi X, Aronowski J, et al. Intra-arterial delivery is not superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke. Stroke J Cereb Circ. 2013;44(12):3463–72.CrossRef
26.
Boltze J, Nitzsche B, Geiger KD, Schoon HA. Histopathological investigation of different MCAO modalities and impact of autologous bone marrow mononuclear cell administration in an ovine stroke model. Transl Stroke Res. 2011;2(3):279–93.CrossRefPubMedPubMedCentral
27.
Womble TA, Green S, Shahaduzzaman M, Grieco J, Sanberg PR, Pennypacker KR, et al. Monocytes are essential for the neuroprotective effect of human cord blood cells following middle cerebral artery occlusion in rat. Mol Cell Neurosci. 2014;59:76–84.CrossRefPubMedPubMedCentral
28.
Patel AR, Ritzel R, McCullough LD, Liu F. Microglia and ischemic stroke: a double-edged sword. Int J Physiol Pathophysiol Pharmacol. 2013;5(2):73–90.PubMedPubMedCentral
29.
Kim JY, Kawabori M, Yenari MA. Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem. 2014;21(18):2076–97.CrossRefPubMedPubMedCentral
Metadata
Title
Various Cell Populations Within the Mononuclear Fraction of Bone Marrow Contribute to the Beneficial Effects of Autologous Bone Marrow Cell Therapy in a Rodent Stroke Model
Authors
Bing Yang
Kaushik Parsha
Krystal Schaar
XiaoPei Xi
Jaroslaw Aronowski
Sean I. Savitz
Publication date
01-08-2016
Publisher
Springer US
Published in
Translational Stroke Research / Issue 4/2016
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-016-0462-x

Other articles of this Issue 4/2016

Translational Stroke Research 4/2016 Go to the issue

SI: Challenges and Controversies in Translational Stroke Research

Strain-Related Differences in the Immune Response: Relevance to Human Stroke

SI: Challenges and Controversies in Translational Stroke Research

Improving Reperfusion Therapies in the Era of Mechanical Thrombectomy

SI: Challenges and Controversies in Translational Stroke Research

The Importance of Considering Sex Differences in Translational Stroke Research

SI: Challenges and Controversies in Translational Stroke Research

Academic-industry Collaborations in Translational Stroke Research

SI: Challenges and Controversies in Translational Stroke Research

Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes

SI: Challenges and Controversies in Translational Stroke Research

Translational Hurdles in Stroke Recovery Studies